• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

白癜风可见度量表的验证:一种患者报告的白癜风治疗成功的结局指标。

Validation of the Vitiligo Noticeability Scale: a patient-reported outcome measure of vitiligo treatment success.

作者信息

Batchelor J M, Tan W, Tour S, Yong A, Montgomery A A, Thomas K S

机构信息

Centre of Evidence Based Dermatology, King's Meadow Campus, Lenton Lane, Nottingham, NG7 2NR, U.K.

Nottingham Clinical Trials Unit, Queen's Medical Centre, C Floor, South Block, Nottingham, NG7 2UH, U.K.

出版信息

Br J Dermatol. 2016 Feb;174(2):386-94. doi: 10.1111/bjd.14208. Epub 2015 Dec 14.

DOI:10.1111/bjd.14208
PMID:26409256
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5019146/
Abstract

BACKGROUND

Patient-reported outcome measures are rarely used in vitiligo trials. The Vitiligo Noticeability Scale (VNS) is a new patient-reported outcome measure assessing how 'noticeable' vitiligo patches are after treatment. The noticeability of vitiligo after treatment is an important indicator of treatment success from the patient's perspective.

OBJECTIVES

To evaluate the construct validity, acceptability and interpretability of the VNS.

METHODS

Clinicians (n = 33) and patients with vitiligo (n = 101) examined 39 image pairs, each depicting a vitiligo lesion pre- and post-treatment. Using an online questionnaire, respondents gave a global assessment of treatment success and a VNS score for treatment response. Clinicians also estimated percentage repigmentation of lesions (< 25%; 25-50%; 51-75%; > 75%). Treatment success was defined as 'yes' on global assessment, a VNS score of 4 or 5, and > 75% repigmentation. Agreement between respondents and the different scales was assessed using kappa (κ) statistics.

RESULTS

Vitiligo Noticeability Scale scores were associated with both patient- and clinician-reported global treatment success (κ = 0·54 and κ = 0·47, respectively). Percentage repigmentation showed a weaker association with patient- and clinician-reported global treatment success (κ = 0·39 and κ = 0·29, respectively). VNS scores of 4 or 5 can be interpreted as representing treatment success. Images depicting post-treatment hyperpigmentation were less likely to be rated as successful.

CONCLUSIONS

The VNS is a valid patient-reported measure of vitiligo treatment success. Further validation of the VNS is required, using larger sets of clinical pre- and post-treatment images, affecting a wider range of anatomical sites.

摘要

背景

患者报告的结局指标在白癜风试验中很少使用。白癜风显著程度量表(VNS)是一种新的患者报告结局指标,用于评估治疗后白癜风斑块的“显著程度”。从患者角度来看,治疗后白癜风的显著程度是治疗成功的重要指标。

目的

评估VNS的结构效度、可接受性和可解释性。

方法

33名临床医生和101名白癜风患者检查了39对图像,每对图像分别描绘了白癜风皮损治疗前后的情况。通过在线问卷,受访者对治疗成功进行整体评估,并对治疗反应给出VNS评分。临床医生还估计皮损的色素恢复百分比(<25%;25 - 50%;51 - 75%;>75%)。治疗成功定义为整体评估为“是”、VNS评分为4或5且色素恢复>75%。使用kappa(κ)统计量评估受访者与不同量表之间的一致性。

结果

白癜风显著程度量表评分与患者和临床医生报告的整体治疗成功均相关(κ分别为0.54和0.47)。色素恢复百分比与患者和临床医生报告的整体治疗成功的相关性较弱(κ分别为0.39和0.29)。VNS评分为4或5可解释为代表治疗成功。描绘治疗后色素沉着过度的图像被评为成功的可能性较小。

结论

VNS是一种有效的患者报告的白癜风治疗成功指标。需要使用更多的临床治疗前后图像集,涵盖更广泛的解剖部位,对VNS进行进一步验证。

相似文献

1
Validation of the Vitiligo Noticeability Scale: a patient-reported outcome measure of vitiligo treatment success.白癜风可见度量表的验证:一种患者报告的白癜风治疗成功的结局指标。
Br J Dermatol. 2016 Feb;174(2):386-94. doi: 10.1111/bjd.14208. Epub 2015 Dec 14.
2
Using the Vitiligo Noticeability Scale in clinical trials: construct validity, interpretability, reliability and acceptability.在临床试验中使用白癜风可见性量表:结构有效性、可解释性、可靠性和可接受性。
Br J Dermatol. 2022 Oct;187(4):548-556. doi: 10.1111/bjd.21671. Epub 2022 Jul 7.
3
Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light Vitiligo three-arm RCT.家庭用窄谱 UVB、局部皮质类固醇或联合治疗儿童和成人白癜风的 HI-Light 白癜风三臂 RCT。
Health Technol Assess. 2020 Nov;24(64):1-128. doi: 10.3310/hta24640.
4
Survey and online discussion groups to develop a patient-rated outcome measure on acceptability of treatment response in vitiligo.开展调查和在线讨论组,以制定一项关于白癜风治疗反应可接受性的患者自评结局指标。
BMC Dermatol. 2014 Jun 14;14:10. doi: 10.1186/1471-5945-14-10.
5
Psychometric Properties and Meaningful Change Thresholds of the Vitiligo Area Scoring Index.白癜风面积评分指数的心理测量学特性及有意义变化阈值
JAMA Dermatol. 2025 Jan 1;161(1):39-46. doi: 10.1001/jamadermatol.2024.4534.
6
International Initiative for Outcomes (INFO) for vitiligo: workshops with patients with vitiligo on repigmentation.国际白癜风结局倡议 (INFO):白癜风患者复色相关的专家研讨会。
Br J Dermatol. 2019 Mar;180(3):574-579. doi: 10.1111/bjd.17013. Epub 2018 Oct 5.
7
Estimating health related quality of life effects in vitiligo. Mapping EQ-5D-5 L utilities from vitiligo specific scales: VNS, VitiQoL and re-pigmentation measures using data from the HI-Light trial.估算白癜风患者的健康相关生命质量影响。使用 HI-Light 试验数据,从 VNS、VitiQoL 和复色测量等白癜风专用量表出发,对 EQ-5D-5L 效用值进行映射。
Health Qual Life Outcomes. 2023 Aug 10;21(1):85. doi: 10.1186/s12955-023-02172-4.
8
Computer-Aided Assessment of Repigmentation Rates in Vitiligo Patients: Implications for Treatment Efficacy - A Retrospective Study.白癜风患者色素再生率的计算机辅助评估:对治疗效果的影响——一项回顾性研究
J Invest Dermatol. 2025 Jan;145(1):56-64.e5. doi: 10.1016/j.jid.2024.05.016. Epub 2024 Jun 22.
9
Which outcomes should we measure in vitiligo? Results of a systematic review and a survey among patients and clinicians on outcomes in vitiligo trials.我们应该在白癜风中测量哪些结果?一项系统评价和一项针对白癜风临床试验结果的患者和临床医生调查的结果。
Br J Dermatol. 2012 Oct;167(4):804-14. doi: 10.1111/j.1365-2133.2012.11056.x.
10
Clinician-reported outcome measures for the assessment of vitiligo: A scoping review.临床医生报告的用于评估白癜风的结局测量指标:范围综述。
J Eur Acad Dermatol Venereol. 2023 Nov;37(11):2231-2242. doi: 10.1111/jdv.19448. Epub 2023 Sep 11.

引用本文的文献

1
Canadian Consensus Guidelines for the Management of Vitiligo.加拿大白癜风管理共识指南
Dermatol Ther (Heidelb). 2025 Jun;15(6):1351-1369. doi: 10.1007/s13555-025-01402-5. Epub 2025 Apr 20.
2
Demographics and Clinical Characteristics among Patients with Distinct Psychosocial Burden Profiles Related to Vitiligo: Results of a Latent Class Analysis.与白癜风相关的不同心理社会负担特征患者的人口统计学和临床特征:潜在类别分析结果
Dermatol Ther (Heidelb). 2025 May;15(5):1195-1208. doi: 10.1007/s13555-025-01401-6. Epub 2025 Apr 10.
3
Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study.

本文引用的文献

1
Developing core outcome set for vitiligo clinical trials: international e-Delphi consensus.制定白癜风临床试验的核心结局集:国际电子德尔菲共识
Pigment Cell Melanoma Res. 2015 May;28(3):363-9. doi: 10.1111/pcmr.12354. Epub 2015 Feb 13.
2
Vitiligo.白癜风。
Lancet. 2015 Jul 4;386(9988):74-84. doi: 10.1016/S0140-6736(14)60763-7. Epub 2015 Jan 15.
3
Survey and online discussion groups to develop a patient-rated outcome measure on acceptability of treatment response in vitiligo.开展调查和在线讨论组,以制定一项关于白癜风治疗反应可接受性的患者自评结局指标。
每日一次口服乌帕替尼对比安慰剂治疗泛发性非节段型白癜风成人患者:一项2期、多中心、随机、双盲、安慰剂对照、剂量范围研究。
EClinicalMedicine. 2024 May 31;73:102655. doi: 10.1016/j.eclinm.2024.102655. eCollection 2024 Jul.
4
Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.评估 1 型神经纤维瘤病临床试验中丛状和皮肤神经纤维瘤相关外观问题的建议。
Clin Trials. 2024 Feb;21(1):6-17. doi: 10.1177/17407745231205577. Epub 2023 Dec 23.
5
Estimating health related quality of life effects in vitiligo. Mapping EQ-5D-5 L utilities from vitiligo specific scales: VNS, VitiQoL and re-pigmentation measures using data from the HI-Light trial.估算白癜风患者的健康相关生命质量影响。使用 HI-Light 试验数据,从 VNS、VitiQoL 和复色测量等白癜风专用量表出发,对 EQ-5D-5L 效用值进行映射。
Health Qual Life Outcomes. 2023 Aug 10;21(1):85. doi: 10.1186/s12955-023-02172-4.
6
Using the Vitiligo Noticeability Scale in clinical trials: construct validity, interpretability, reliability and acceptability.在临床试验中使用白癜风可见性量表:结构有效性、可解释性、可靠性和可接受性。
Br J Dermatol. 2022 Oct;187(4):548-556. doi: 10.1111/bjd.21671. Epub 2022 Jul 7.
7
Development of a core outcome domain set for clinical research on capillary malformations (the COSCAM project).制定毛细血管畸形临床研究的核心结局领域集(COSCAM 项目)。
J Eur Acad Dermatol Venereol. 2021 Sep;35(9):1888-1895. doi: 10.1111/jdv.17376. Epub 2021 Jun 16.
8
Design and Implementation of a Heating Treatment System for Vitiligo Skin Disease Based on Medical Ultrasound.基于医学超声的白癜风皮肤病加热治疗系统的设计与实现。
J Healthc Eng. 2021 Mar 9;2021:6634846. doi: 10.1155/2021/6634846. eCollection 2021.
9
Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light Vitiligo three-arm RCT.家庭用窄谱 UVB、局部皮质类固醇或联合治疗儿童和成人白癜风的 HI-Light 白癜风三臂 RCT。
Health Technol Assess. 2020 Nov;24(64):1-128. doi: 10.3310/hta24640.
10
Home interventions and light therapy for the treatment of vitiligo (HI-Light Vitiligo Trial): study protocol for a randomised controlled trial.家庭干预与光疗治疗白癜风(HI-Light白癜风试验):一项随机对照试验的研究方案
BMJ Open. 2018 Apr 3;8(4):e018649. doi: 10.1136/bmjopen-2017-018649.
BMC Dermatol. 2014 Jun 14;14:10. doi: 10.1186/1471-5945-14-10.
4
Measurement properties of the Vitiligo Impact Scale-22 (VIS-22), a vitiligo-specific quality-of-life instrument.白癜风影响量表-22(VIS-22)的测量特性,一种专门针对白癜风的生活质量工具。
Br J Dermatol. 2014 Nov;171(5):1084-90. doi: 10.1111/bjd.13093. Epub 2014 Oct 6.
5
Kappa statistic for clustered dichotomous responses from physicians and patients.医生和患者的聚类二分类反应的 Kappa 统计量。
Stat Med. 2013 Sep 20;32(21):3700-19. doi: 10.1002/sim.5796. Epub 2013 Mar 27.
6
Vitiligo impact scale: an instrument to assess the psychosocial burden of vitiligo.白癜风影响量表:评估白癜风患者心理社会负担的工具。
Indian J Dermatol Venereol Leprol. 2013 Mar-Apr;79(2):205-10. doi: 10.4103/0378-6323.107637.
7
Which outcomes should we measure in vitiligo? Results of a systematic review and a survey among patients and clinicians on outcomes in vitiligo trials.我们应该在白癜风中测量哪些结果?一项系统评价和一项针对白癜风临床试验结果的患者和临床医生调查的结果。
Br J Dermatol. 2012 Oct;167(4):804-14. doi: 10.1111/j.1365-2133.2012.11056.x.
8
Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL).开发和验证一种白癜风特异性生活质量工具(VitiQoL)。
J Am Acad Dermatol. 2013 Jul;69(1):e11-8. doi: 10.1016/j.jaad.2012.01.038. Epub 2012 Feb 25.
9
Quality-of-life issues in vitiligo.白癜风的生活质量问题。
Dermatol Clin. 2012 Apr;30(2):255-68, viii. doi: 10.1016/j.det.2011.11.013. Epub 2011 Dec 15.
10
Guidelines for designing and reporting clinical trials in vitiligo.白癜风临床试验设计与报告指南
Arch Dermatol. 2011 Dec;147(12):1428-36. doi: 10.1001/archdermatol.2011.235. Epub 2011 Aug 15.